The present disclosure relates to the use of l-[4-bromo-5-[l-ethyl-7-(methylamino)-2- oxo-l,2-dihydro-l,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or l-(5-(7-amino-l- ethyl-2-oxo-l,2-dihydro-l,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.